Targeted radionuclide therapy for neuroendocrine tumours: Principles and application

Neuroendocrinology

Volumn 91, Issue 1, 2010, Pages 1-15

  Druce, Maralyn R ^a   Lewington, Val ^b   Grossman, Ashley B ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Carcinoid; Gastroenteropancreatic neuroendocrine tumours; Neuroendocrine tumours; Phaeochromocytoma; Radionuclide

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID 1 NAL3 OCTREOTIDE IN 111; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID DEXTRO PHENYLALANYLTYROSINE 3 OCTREOTIDE Y 90; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LANREOTIDE Y 90; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSINE 3 OCTREOTATE LU 177; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSINE 3 OCTREOTATE Y 90; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSINE 3 OCTREOTIDE Y 90; ANTINEOPLASTIC AGENT; CORTICOSTEROID; INDIUM 111; IODINE 131; LUTETIUM 177; OCTREOTIDE; PENTETIC ACID OCTREOTIDE INDIUM 111; PENTETREOTIDE IN 111; PHOSPHORUS 32; PLACEBO; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RHENIUM 186; SAMARIUM 153; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; STRONTIUM 89; UNCLASSIFIED DRUG; YTTRIUM 90;

ABDOMINAL PAIN; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER RADIOTHERAPY; CELL DEATH; CLINICAL FEATURE; CLINICAL TRIAL; DOSIMETRY; DRUG EFFECT; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; FIELD EMISSION; GAMMA RADIATION; HUMAN; ISOTOPE LABELING; LEUKOCYTE COUNT; LIVER TOXICITY; MYELODYSPLASTIC SYNDROME; NAUSEA; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; NONHUMAN; PARAGANGLIOMA; PARTICLE RADIATION; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING;

ANIMALS; HUMANS; NEUROENDOCRINE TUMORS; RADIOISOTOPES; RADIOPHARMACEUTICALS; RADIOTHERAPY;

EID: 76749140359     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000227808     Document Type: Review

References (73)

1. Rufini V, Calcagni ML, Baum RP: Imaging of neuroendocrine tumors. Semin Nucl Med 2006; 36: 228-247.
2. Mothersill C, Seymour CB: Targeted radiotherapy: is the 'Holy Grail' in sight? J Nucl Med 2006; 47: 899-900.
3. Mothersill C, Seymour C: Radiation-induced bystander and other non-targeted effects: novel intervention points in cancer therapy? Curr Cancer Drug Targets 2006; 6: 447-454.
4. Podoloff DA: Diagnostic and therapeutic applications of radiolabeled somatostatin analogs: current status in an oncology center. Curr Pharm Des 2002; 8: 1809-1814.
5. Krenning EP, de Jong M, Kooij PP, Breeman WA, Bakker WH, de Herder WW, van Eijck CH, Kwekkeboom DJ, Jamar F, Pauwels S, Valkema R: Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol 1999; 10(suppl 2):S23-S29.
6. de Jong M, Kwekkeboom D, Valkema R, Krenning EP: Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002. Eur J Nucl Med Mol Imaging 2003; 30: 463-469.
7. Kassis AI, Adelstein SJ: Radiobiologic principles in radionuclide therapy. J Nucl Med 2005; 46(suppl 1):4S-12S.
8. International Union of Pure and Applied Chemistry. 2008 Compendium of Chemical Terminology Internet edition.
9. Kassis AI: Radiotargeting agents for cancer therapy. Expert Opin Drug Deliv 2005; 2: 981-991.
10. Lewington VJ: Targeted radionuclide therapy for neuroendocrine tumours. Endocr Relat Cancer 2003; 10: 497-501.
11. Capello A, Krenning EP, Breeman WA, Bernard BF, de Jong M: Peptide receptor radionuclide therapy in vitro using [111In- DTPA0]octreotide. J Nucl Med 2003; 44: 98-104.
12. Royal College of Physicians: Radioiodine in the management of benign thyroid disease. A4 report, June 2007. http://www.rcplondon. ac.uk/pubs/contents/0621b67a-4880-4a1b- 9942-57a666efee4a.pdf.
13. Mukherjee JJ, Kaltsas GA, Islam N, Plowman PN, Foley R, Hikmat J, Britton KE, Jenkins PJ, Chew SL, Monson JP, Besser GM, Grossman AB: Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG]. Clin Endocrinol (Oxf) 2001; 55: 47-60.
14. Krenning EP, Teunissen JJ, Valkema R, de- Herder WW, deJong M, Kwekkeboom DJ: Molecular radiotherapy with somatostatin analogs for (neuro-)endocrine tumors. J Endocrinol Invest 2005; 28: 146-150.
15. Krenning EP, Kwekkeboom DJ, Valkema R, Pauwels S, Kvols LK, de Jong M: Peptide receptor radionuclide therapy. Ann N Y Acad Sci 2004; 1014: 234-245.
16. de Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, Bakker WH, Smith C, Pauwels S, Krenning EP: Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 2002; 32: 133-140.
17. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, O'Dorisio TM, Valkema R, Bodei L, Chinol M, Maecke HR, Krenning EP: Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005; 46(suppl 1):62S-66S. (Pubitemid 47619020)
18. Bodei L, Cremonesi M, Grana C, Rocca P, Bartolomei M, Chinol M, Paganelli G: Receptor radionuclide therapy with 90Y- [DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004; 31: 1038-1046.
19. Kaltsas GA, Besser GM, Grossman AB: The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004; 25: 458-511.
20. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC: The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-oflife instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.
21. Davies AH, Larsson G, Ardill J, Friend E, Jones L, Falconi M, Bettini R, Koller M, Sezer O, Fleissner C, Taal B, Blazeby JM, Ramage JK: Development of a disease-specific Quality of Life questionnaire module for patients with gastrointestinal neuroendocrine tumours. Eur J Cancer 2006; 42: 477-484.
22. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216. (Pubitemid 30099779)
24. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
25. Anon. Tumour response criteria. 2008. Internet Communication. http://www.ahrg. gov/clinic/ta/gist/gisttab2.htm.
26. Kaltsas GA, Papadogias D, Makras P, Grossman AB: Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Endocr Relat Cancer 2005; 12: 683-699.
27. Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB: The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer 2007; 14: 569-585.
28. Ahlman H: Malignant pheochromocytoma: state of the field with future projections. Ann N Y Acad Sci 2006; 1073: 449-464.
29. Kolby L, Bernhardt P, Johanson V, Wangberg B, Muth A, Jansson S, Forssell-Aronsson E, Nilsson O, Ahlman H: Can quantification of VMAT and SSTR expression be helpful for planning radionuclide therapy of malignant pheochromocytomas? Ann N Y Acad Sci 2006; 1073: 491-497.
30. Rose B, Matthay KK, Price D, Huberty J, Klencke B, Norton JA, Fitzgerald PA: Highdose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer 2003; 98: 239-248.
31. Lawrence JK, Maher ER, Sheaves R, Grossman AB: Familial paraganglioma: a novel presentation of a case and response to therapy with radiolabelled MIBG. Hormones (Athens) 2004; 3: 127-131.
32. Lam MG, Lips CJ, Jager PL, Dullaart RP, Lentjes EG, van Rijk PP, de Klerk JM: Repeated [131I]metaiodobenzylguanidine therapy in two patients with malignant pheochromocytoma. J Clin Endocrinol Metab 2005; 90: 5888-5895.
33. Garaventa A, Gambini C, Villavecchia G, Di Cataldo A, Bertolazzi L, Pizzitola MR, De Bernardi B, Haupt R: Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine. Cancer 2003; 97: 1332-1338.
34. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Macke HR: Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000; 27: 273-282.
35. van Essen M, Krenning EP, de Jong M, Valkema R, Kwekkeboom DJ: Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol 2007; 46: 723-734. (Pubitemid 47123757)
36. Arnold R, Wied M, Behr TH: Somatostatin analogues in the treatment of endocrine tumors of the gastrointestinal tract. Expert Opin Pharmacother 2002; 3: 643-656.
37. Oberg K: Management of neuroendocrine tumours. Ann Oncol 2004; 15(suppl 4): iv293-iv298.
38. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle FG, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A: Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008; 9: 61-72.
39. Rohrer L, Raulf F, Bruns C, Buettner R, Hofstaedter F, Schule R: Cloning and characterization of a fourth human somatostatin receptor. Proc Natl Acad Sci USA 1993; 90: 4196-4200.
40. Panetta R, Greenwood MT, Warszynska A, Demchyshyn LL, Day R, Niznik HB, Srikant CB, Patel YC: Molecular cloning, functional characterization, and chromosomal localization of a human somatostatin receptor (somatostatin receptor type 5) with preferential affinity for somatostatin-28. Mol Pharmacol 1994; 45: 417-427.
41. Patel YC, Greenwood M, Panetta R, Hukovic N, Grigorakis S, Robertson LA, Srikant CB: Molecular biology of somatostatin receptor subtypes. Metabolism 1996; 45: 31-38.
42. Hofland LJ, Lamberts SW, van Hagen PM, Reubi JC, Schaeffer J, Waaijers M, van Koetsveld PM, Srinivasan A, Krenning EP, Breeman WA: Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs. J Nucl Med 2003; 44: 1315-1321.
43. John M, Meyerhof W, Richter D, Waser B, Schaer JC, Scherubl H, Boese-Landgraf J, Neuhaus P, Ziske C, Molling K, Riecken EO, Reubi JC, Wiedenmann B: Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2. Gut 1996; 38: 33-39.
44. de Herder WW, Hofland LJ, van der Lely AJ, Lamberts SW: Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocr Relat Cancer 2003; 10: 451-458.
45. Teunissen JJ, Kwekkeboom DJ, de Jong M, Esser JP, Valkema R, Krenning EP: Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy. Best Pract Res Clin Gastroenterol 2005; 19: 595-616.
46. Reubi JC: Somatostatin and other peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology 2004; 80(suppl 1):51-56.
47. Anthony LB, Woltering EA, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE: Indium- 111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 2002; 32: 123-132.
48. Buscombe JR, Caplin ME, Hilson AJ: Longterm efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors. J Nucl Med 2003; 44: 1-6.
49. Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, Maecke HR, Muller J: Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 1999; 26: 1439-1447.
50. Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J: The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001; 12: 941-945.
51. Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, Haldemann A, Mueller-Brand J: Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 2002; 43: 610-616.
52. Paganelli G, Bodei L, Handkiewicz JD, Rocca P, Papi S, Lopera SM, Gatti M, Chinol M, Bartolomei M, Fiorenza M, Grana C: 90YDOTA- D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies. Biopolymers 2002; 66: 393-398.
53. Bushnell D, O'Dorisio T, Menda Y, Carlisle T, Zehr P, Connolly M, Karwal M, Miller S, Parker S, Bouterfa H: Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors. J Nucl Med 2003; 44: 1556-1560.
54. Valkema R, Pauwels S, Kvols LK, Barone R, Jamar F, Bakker WH, Kwekkeboom DJ, Bouterfa H, Krenning EP: Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2006; 36: 147-156.
55. Virgolini I, Traub T, Novotny C, Leimer M, Fuger B, Li SR, Patri P, Pangerl T, Angelberger P, Raderer M, Burggasser G, Andreae F, Kurtaran A, Dudczak R: Experience with indium-111 and yttrium-90-labeled somatostatin analogs. Curr Pharm Des 2002; 8: 1781-1807.
56. Leimer M, Kurtaran A, Smith-Jones P, Raderer M, Havlik E, Angelberger P, Vorbeck F, Niederle B, Herold C, Virgolini I: Response to treatment with yttrium 90-DOTA-lanreotide of a patient with metastatic gastrinoma. J Nucl Med 1998; 39: 2090-2094.
57. Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P: In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 2002; 32: 148-155.
58. van Essen M, Krenning EP, Bakker WH, de Herder WW, van Aken MO, Kwekkeboom DJ: Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin. Eur J Nucl Med Mol Imaging 2007; 34: 1219-1227.
59. van Essen M, Krenning EP, Kooij PP, Bakker WH, Feelders RA, de Herder WW, Wolbers JG, Kwekkeboom DJ: Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med 2006; 47: 1599-1606.
60. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO, Krenning EP: Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008; 26: 2124-2130.
61. Pauwels S, Barone R, Walrand S, Borson- Chazot F, Valkema R, Kvols LK, Krenning EP, Jamar F: Practical dosimetry of peptide receptor radionuclide therapy with (90)Ylabeled somatostatin analogs. J Nucl Med 2005; 46(suppl 1):92S-98S. (Pubitemid 47619024)
62. Kwekkeboom DJ, Teunissen JJ, Kam BL, Valkema R, de Herder WW, Krenning EP: Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analogues. Hematol Oncol Clin North Am 2007; 21: 561-573.
63. de Keizer B, van Aken MO, Feelders RA, de Herder WW, Kam BL, van Essen M, Krenning EP, Kwekkeboom DJ: Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [(177)Lu-DOTA (0),Tyr (3)]octreotate. Eur J Nucl Med Mol Imaging 2008; 35: 749-755.
64. Valkema R, de Jong M, Bakker WH, Breeman WA, Kooij PP, Lugtenburg PJ, De Jong FH, Christiansen A, Kam BL, de Herder WW, Stridsberg M, Lindemans J, Ensing G, Krenning EP: Phase I study of peptide receptor radionuclide therapy with [In - DTPA]octreotide: the Rotterdam experience. Semin Nucl Med 2002; 32: 110-122.
65. Otte A, Weiner SM, Cybulla M: Is radiation nephropathy caused by yttrium-90? Lancet 2002; 359: 979.
66. Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, Barone R, Walrand S, Kooij PP, Bakker WH, Lasher J, Krenning EP: Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med 2005; 46(suppl 1):83S-91S.
67. de Jong M, Breeman WA, Valkema R, Bernard BF, Krenning EP: Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med 2005; 46(suppl 1):13S-17S.
68. O'Donoghue JA, Bardies M, Wheldon TE: Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 1995; 36: 1902-1909.
69. Kunikowska J, Mikolajczak R, Pawlak D, Hubalewska-Dydejczyk A, Sowa-Staszczak A, Kobylecka M: Clinical results of PPRT with 90 Y-DOTATATE and 90 Y/ 177 Lu- DOTATATE - What is better for therapy (abstract C61. 6th Ann ENETS Conf, March 2009, Granada).
70. Chatal JF, Le Bodic MF, Kraeber-Bodere F, Rousseau C, Resche I: Nuclear medicine applications for neuroendocrine tumors. World J Surg 2000; 24: 1285-1289.
71. Kaltsas G, Rockall A, Papadogias D, Reznek R, Grossman AB: Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur J Endocrinol 2004; 151: 15-27.
72. Smith-Jones PM, Bischof C, Leimer M, Gludovacz D, Angelberger P, Pangerl T, Peck- Radosavljevic M, Hamilton G, Kaserer K, Kofler A, Schlangbauer-Wadl H, Traub T, Virgolini I: DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy. Endocrinology 1999; 140: 5136-5148. (Pubitemid 30687123)
73. Wild D, Schmitt JS, Ginj M, Macke HR, Bernard BF, Krenning E, de Jong M, Wenger S, Reubi JC: DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 2003; 30: 1338-1347.